These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 35716351)
21. [Mutations of peroxisome proliferator-activated receptor gamma (PPARgamma): clinical implications]. Gacka M; Adamiec R Postepy Hig Med Dosw (Online); 2004; 58():483-9. PubMed ID: 15765009 [TBL] [Abstract][Full Text] [Related]
22. Fat Mass Reduction With Adipocyte Hypertrophy and Insulin Resistance in Heterozygous PPARγ Mutant Rats. Gumbilai V; Ebihara K; Aizawa-Abe M; Ebihara C; Zhao M; Yamamoto Y; Mashimo T; Hosoda K; Serikawa T; Nakao K Diabetes; 2016 Oct; 65(10):2954-65. PubMed ID: 27381370 [TBL] [Abstract][Full Text] [Related]
23. Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Risérus U; Tan GD; Fielding BA; Neville MJ; Currie J; Savage DB; Chatterjee VK; Frayn KN; O'Rahilly S; Karpe F Diabetes; 2005 May; 54(5):1379-84. PubMed ID: 15855323 [TBL] [Abstract][Full Text] [Related]
24. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Tenenbaum A; Fisman EZ Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952 [TBL] [Abstract][Full Text] [Related]
25. A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice. Shiomi Y; Yamauchi T; Iwabu M; Okada-Iwabu M; Nakayama R; Orikawa Y; Yoshioka Y; Tanaka K; Ueki K; Kadowaki T J Biol Chem; 2015 Jun; 290(23):14567-81. PubMed ID: 25907553 [TBL] [Abstract][Full Text] [Related]
26. Lessons from human mutations in PPARgamma. Hegele RA Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581 [TBL] [Abstract][Full Text] [Related]
28. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPARgamma-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population. Meshkani R; Taghikhani M; Larijani B; Bahrami Y; Khatami S; Khoshbin E; Ghaemi A; Sadeghi S; Mirkhani F; Molapour A; Adeli K Clin Chem Lab Med; 2007; 45(4):477-82. PubMed ID: 17439324 [TBL] [Abstract][Full Text] [Related]
29. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. Evans JL; Lin JJ; Goldfine ID Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606 [TBL] [Abstract][Full Text] [Related]
30. PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine. Cataldi S; Costa V; Ciccodicola A; Aprile M Curr Diab Rep; 2021 Apr; 21(6):18. PubMed ID: 33866450 [TBL] [Abstract][Full Text] [Related]
31. Phenotypic Characterization of Mice Carrying Homozygous Deletion of KLF11, a Gene in Which Mutations Cause Human Neonatal and MODY VII Diabetes. Mathison A; Escande C; Calvo E; Seo S; White T; Salmonson A; Faubion WA; Buttar N; Iovanna J; Lomberk G; Chini EN; Urrutia R Endocrinology; 2015 Oct; 156(10):3581-95. PubMed ID: 26248217 [TBL] [Abstract][Full Text] [Related]
33. Analysis of the peroxisome proliferator activated receptor gamma (PPARgamma) gene in HAIRAN syndrome with obesity. Globerman H; Zauberman Y; Makarov T; Beamer BA; Yen CJ; Shuldiner AR; Harel C; Karnieli E Clin Endocrinol (Oxf); 2000 Apr; 52(4):479-85. PubMed ID: 10762291 [TBL] [Abstract][Full Text] [Related]
34. Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome. Sinha SK; Bhangoo A; Anhalt H; Maclaren N; Marshall JD; Collin GB; Naggert JK; Ten S J Pediatr Endocrinol Metab; 2007 Sep; 20(9):1045-52. PubMed ID: 18038714 [TBL] [Abstract][Full Text] [Related]
35. Genetics of type 2 diabetes mellitus and other specific types of diabetes; its role in treatment modalities. Kota SK; Meher LK; Jammula S; Kota SK; Modi KD Diabetes Metab Syndr; 2012; 6(1):54-8. PubMed ID: 23014256 [TBL] [Abstract][Full Text] [Related]
36. Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment. Takasawa K; Kubota N; Terauchi Y; Kadowaki T Endocr J; 2008 Aug; 55(4):767-76. PubMed ID: 18506083 [TBL] [Abstract][Full Text] [Related]
38. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Dumasia R; Eagle KA; Kline-Rogers E; May N; Cho L; Mukherjee D Curr Drug Targets Cardiovasc Haematol Disord; 2005 Oct; 5(5):377-86. PubMed ID: 16248830 [TBL] [Abstract][Full Text] [Related]
39. Pparg-P465L mutation worsens hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and storage dysfunction. Pendse AA; Johnson LA; Tsai YS; Maeda N Diabetes; 2010 Nov; 59(11):2890-7. PubMed ID: 20724579 [TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Jay MA; Ren J Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]